| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Biora Therapeutics (NASDAQ:BIOR) will release its quarterly earnings report on Thursday, 2024-11-14. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Biora Therapeutics to report an earnings per share (EPS) of $-3.80.
Biora Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
During the last quarter, the company reported an EPS beat by $4.10, leading to a 14.81% increase in the share price on the subsequent day.
Here's a look at Biora Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -4.5 | -4.5 | -5.9 | -7.6 |
| EPS Actual | -0.4 | -1.4 | -6.3 | -7.5 |
| Price Change % | 15.0% | 3.0% | -12.0% | -2.0% |
Shares of Biora Therapeutics were trading at $2.7 as of November 12. Over the last 52-week period, shares are down 79.96%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
To track all earnings releases for Biora Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BIOR
